Aditxt Inc. to Showcase Adimune's Innovations in Autoimmune Therapeutics During July 22 Livestream

Aditxt Inc. (NASDAQ: ADTX), a leader in advancing health solutions through its social innovation platform, has announced a livestream event scheduled for July 22, 2025, at 1:00 p.m. ET. The event will focus on Adimune Inc., Aditxt's subsidiary specializing in autoimmune therapeutics. Hosted by Jack Marks of Wall Street Reporter, the livestream will feature Aditxt Co-founder and CEO Amro Albanna, who will delve into Adimune's innovative strategies, upcoming milestones, and the vast opportunities within the autoimmune disease market.

The autoimmune disease market is experiencing significant growth, driven by increasing prevalence rates and the urgent need for innovative treatments. Adimune's approach to tackling these challenges positions Aditxt as a key player in the healthcare innovation space. The livestream aims to shed light on how Adimune's work could potentially transform treatment paradigms for millions of patients worldwide.

Aditxt's unique model of democratizing innovation and fostering collaboration among research institutions, industry partners, and shareholders underscores its commitment to addressing some of the most pressing health challenges. With plans to expand its programs to include public health and women's health, Aditxt is poised to broaden its impact. The company's strategic agreements with Appili Therapeutics Inc. and Evofem are steps toward realizing this vision, although the completion of these transactions is contingent upon meeting certain conditions.

This livestream represents a significant opportunity for stakeholders to gain insights into Adimune's contributions to the field of autoimmune therapeutics and Aditxt's overarching mission to accelerate health innovations. For more information on Aditxt and its initiatives, visit https://www.Aditxt.com.